Interim report 2026
Filed with HKEX · Stock code 2617 · · 59 pages · English
TransThera Sciences (Nanjing). Inc. on 6ix
Earlier from TransThera Sciences (Nanjing)
- Voluntary announcement first patient dosed in phase II clinical trial of tinengotinib in combination with novel hormonal therapy for pretreated and progressed metastatic castration-resistant prostate cancer in China
- Voluntary announcement inclusion of yochanra (tinengotinib) in the CSCO guidelines for the diagnosis and treatment of biliary tract cancers (2026)
- New drug application for Tinengotinib tablets accepted by the national medical products administration
- TransThera Publishes Clinical Studies of Tinengotinib (TT-00420) against Cholangiocarcinoma on Lancet
- Inclusion of Tinengotinib tablets in the list of products for priority review by the national medical products administration
Later from TransThera Sciences (Nanjing)
All TransThera Sciences (Nanjing) news releasesFollow TransThera Sciences (Nanjing) into a list and get an email when it puts out news.
Follow TransThera Sciences (Nanjing)